Deals channel feed

Covid-19 could throw fi­nal hur­dle in­to Ab­b­Vie and Al­ler­gan’s mas­sive merg­er

6 years ago
R&D

The big C: The deal­mak­ers, dol­lars and dis­eases that have trans­formed the Chi­nese bio­phar­ma mar­ket

6 years ago
Financing
China

An­oth­er an­tibi­ot­ic mak­er bites the dust, as Tetraphase is swal­lowed for cheap

6 years ago
Pharma

Flag­ship merges two star­tups to build a $220M Reper­toire of T cell tech, ther­a­pies

6 years ago

Af­ter a year of big ad­vances, As­traZeneca CEO Pas­cal So­ri­ot takes home a ma­jor-league pay pack­age

6 years ago
People

Stan­ford stem cell pi­o­neer nets $194M from Gilead-Forty Sev­en buy­out

6 years ago
People

A JP Mor­gan promise, a last-minute bid and the coro­n­avirus stock mar­ket — how Gilead’s Daniel O’Day nabbed Forty Sev­en

6 years ago
R&D

Neil Wood­ford in the game to buy back his for­mer un­list­ed port­fo­lio that's prov­ing hard to sell — re­ports

6 years ago
Financing

Ahead of cru­cial PhII read­out, Sh­iono­gi lines up an op­tion to buy out biotech part­ner and its non-amy­loid Alzheimer's drug

6 years ago

Ab­b­Vie and Al­ler­gan fi­nal­ly set (rough) date for wed­ding as one par­ent agrees to the match

6 years ago
R&D

Hap­py alone Qi­a­gen changes course af­ter Ther­mo Fish­er of­fers to buy it in $11.5B deal

6 years ago

In pos­si­ble sign of things to come, Daniel O’Day’s new-look Gilead bets $4.9B on can­cer biotech

6 years ago

A name emerges out of the Gilead M&A ru­mor mill, and it’s a can­cer biotech

6 years ago

Bio­gen makes an­oth­er bold Alzheimer’s bet, drop­ping $350M up­front to part­ner with genome-edit­ing fo­cused Sang­amo

6 years ago
Cell/Gene Tx

Will a 'risk-of­f' mind­set has­ten cell ther­a­py M&A? Io­vance surges on buy­out chat­ter

6 years ago
Cell/Gene Tx

Take­da swoops in to buy lit­tle biotech part­ner and its celi­ac drug poised to 'change stan­dard of care'

6 years ago

Bi­cy­cle Ther­a­peu­tics takes Roche's Genen­tech on an up to $2B im­muno-on­col­o­gy ride

6 years ago

When drug val­ue as­sess­ment meets re­al-world ev­i­dence: ICER en­lists Ae­tion in pric­ing eval­u­a­tion

6 years ago

Mallinck­rodt, once the na­tion’s largest oxy­codone pro­duc­er, an­nounces ten­ta­tive $1.6B set­tle­ment

6 years ago
Pharma

Har­vard joins coro­n­avirus fight with $115M and a high-pro­file Chi­nese part­ner

6 years ago
China
Coronavirus

As coro­n­avirus out­break reach­es 'tip­ping point,' GSK lends ad­ju­vant tech to Chi­nese part­ner armed with pre­clin­i­cal vac­cine

6 years ago
China
Coronavirus

Bank­rupt an­tibi­otics mak­er Ar­a­digm turns to old part­ner/in­vestor for fi­nal $3M fire sale

6 years ago

Say good­bye to Toca­gen, strug­gling brain can­cer biotech to re­verse merge with Forte Bio­sciences

6 years ago

Don't let Ab­b­Vie fool FTC with an easy di­vesti­ture, plead crit­ics in lat­est at­tack on $63B Al­ler­gan buy­out

6 years ago
Pharma
First page Previous page 93949596979899 Next page Last page
A service from the Financial Times